阿尔茨海默病中的α-synuclein沉积模式:与皮质粉样蛋白β和可变的tau负载相关
Antonia Neubauer1,2,3, Doris Weissenbrunner4,5, Susanna Pekrun4,5
1Center for Neuropathology and Prion Research, Ludwig Maximilians University of Munich, Munich, Germany. Antonia.Neubauer@med.uni-muenchen.de.
Acta neuropathologica
|October 30, 2025
概括
在许多阿尔茨海默氏症患者中发现了α-synuclein (α-syn) 沉积物.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
背景情况:
- 在约50%的阿尔茨海默氏病 (AD) 病例中存在α-synuclein (α-syn) 沉积物.
- 在阿尔茨海默氏症中,α-syn,β-粉样蛋白 (Aβ) 和tau病理之间的相互作用尚未得到充分理解.
研究的目的:
- 为了研究阿尔茨海默病患者大脑中的α-syn,Aβ和tau的分布模式.
- 探索α-syn负载,其解剖分布和AD神经病理特征之间的关系.
- 检查与人口统计学因素的关联,如年龄,性别和ApoE基因型.
主要方法:
- 使用随机森林像素分类器对蛋白质沉积 (α-syn,Aβ,tau) 的自动量化量化.
- 在72个患有晚期阿尔茨海默病的大脑中,分析了多达28个大脑区域的免疫组织化学污点.
- 根据α-syn分布对病例进行分类:阴性,杏仁体占主导,脑干占主导,皮质.
主要成果:
- 在60%的AD病例中观察到α-syn共同病理,女性的患病率趋向于更高.
- 在50%的阳性病例中发现了皮层α-syn沉积物,其他病例主要在杏仁体或脑干中发现.
- 杏仁体α-syn负载与皮质Aβ负载增加相关;tau负载根据α-syn分布变化.
- ApoE4基因型与较高的海马α-syn和皮质Aβ沉积有关.
- 较年轻的死亡年龄与较高的焦点Aβ/tau负荷和皮质α-syn沉积有关.
结论:
- 在AD中α-syn病理的分布受到年龄,性别和ApoE基因型的影响,并且与明显的Aβ和tau负载有关.
- 了解α-syn分布模式可能会为针对性治疗的患者分层提供信息,例如Aβ免疫疗法.
- 定义α-syn病理及其在AD早期的分布对于治疗开发和患者管理至关重要.
更多相关视频
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
11.2K
09:16Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
Published on: June 26, 2018
8.0K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Amyloid Fibrils
6.3K
6.3K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
